A prospective, open label protocol to assess the efficacy and safety of enteric-coated mycophenolate sodium in de novo kidney transplant recipients.
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Mycophenolate sodium (Primary) ; Ciclosporin; Corticosteroids
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Nov 2009 Actual end date (Jun 2006) added as reported by ClinicalTrials.gov.
- 19 Dec 2005 New trial record.